Ubs Group Ag Exicure, Inc. Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.3 - $0.64 $4,644 - $9,907	15,480 Added 845.44%	17,311 $5,000
Q1 2024 May 13, 2024	BUY	$0.53 - $0.84 $65 - $104	124 Added 7.26%	1,831 $1,000
Q3 2023 Nov 09, 2023	SELL	$0.71 - $1.36 $63 - $121	-89 Reduced 4.96%	1,707 $1,000
Q2 2023 Aug 11, 2023	SELL	$0.85 - $1.44 $73 - $123	-86 Reduced 4.57%	1,796 $2,000
Q1 2023 May 12, 2023	SELL	$0.78 - $1.58 $7,463 - $15,119	-9,569 Reduced 83.56%	1,882 $1,000
Q4 2022 Feb 08, 2023	BUY	$0.71 - $9.3 $6,977 - $91,400	9,828 Added 605.55%	11,451 $13,000
Q3 2022 Nov 10, 2022	BUY	$1.53 - $8.5 $1,973 - $10,965	1,290 Added 387.39%	1,623 $3,000
Q2 2022 Aug 10, 2022	BUY	$2.16 - $6.36 $719 - $2,117	333 New	333 $1,000

287K

Ticker XCUR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,962,580
Market Cap $92.7M
Description
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.